Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 531 in thrombocytopenic ITP patients prior to splenectomy
2004-000173-65Phase 3Completed
- Sponsor
- Amgen
- Start
- Feb 2005
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in immune thrombocytopenia (ITP) comparing Romiplostim with Placebo (2 arms). Primary endpoints: Durable platelet response and Safety of romiplostim. Started Feb 2005; status: completed.
02
Drugs
romiplostim
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on 2004-000173-65.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000173-65.